IgD Myeloma with Mott Cells, Adverse Prognosis Cytogenetics and Persistent Minute IgD M-Protein Following Treatment

Philip A Egan1, Ian Deighan W2, Sheila JM O’Connor3, Conal E McConville4, Patrick T Elder4, Priyank Shukla1, T C M (Curly) Morris5 and Denis Alexander H1*

1N Ireland Centre for Stratified Medicine, Altnagelvin Area Hospital, Ulster University, N Ireland
2Department of Clinical Chemistry, Altnagelvin Area Hospital, N Ireland
3Hematological Malignancy Diagnostic Service, St James’s Institute of Oncology, England, UK
4Department of Hematology, Altnagelvin Area Hospital, N Ireland
5Patrick G Johnston Centre for Cancer Research, Queen’s University, UK

^*Correspondance to: Denis Alexander H 

 PDF  Full Text Case Report | Open Access

Abstract:

Immunoglobulin D-secreting Multiple Myeloma (IgD MM) is a rare form of the disease, accounting for 1% to 2% of cases. Patients present frequently at a younger age and with more advanced disease than in the more common myeloma isotypes, contributing to shorter Overall Survival (OS) and Progression Free Survival (PFS). Autologous Stem Cell Transplant (ASCT) and greater access to novel agents are key to reducing this gap. As with other myeloma isotypes, there is a small group of long-term survivors. Interphase Fluorescence in situ Hybridization (iFISH) detects abnormalities in the majority of cases. 1q21 amplification, associated with late myeloma, and t(11;14), are more common than in other myeloma isotypes. No clear difference in del(17p) frequency has been shown. We present a case report of an IgD MM patient in our care which, whilst not entirely typical of the genre, illustrates the diagnostic and management challenges when caring for these patients.

Keywords:

Cite the Article:

Egan PA, Ian Deighan W, O’Connor SJM, McConville CE, Elder PT, Shukla P, et al. IgD Myeloma with Mott Cells, Adverse Prognosis Cytogenetics and Persistent Minute IgD M-Protein Following Treatment. Ann Clin Case Rep. 2022; 7: 2276..